Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:002773)

SHE:002773 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	3,334	5,690	4,702	3,585	2,939	3,328
Trading Asset Securities	2,665	-	-	100	200	-
Cash & Short-Term Investments	5,999	5,690	4,702	3,685	3,139	3,328
Cash Growth	17.18%	21.00%	27.59%	17.41%	-5.67%	45.71%
Accounts Receivable	202.38	177.85	160.41	160.69	204.63	346.2
Other Receivables	24.74	23.04	28.81	27.88	43.59	25.57
Receivables	227.12	200.89	189.22	188.57	248.22	371.77
Inventory	373.45	386.86	403.61	330.96	295.62	239.64
Other Current Assets	33.14	11.56	10.63	24.22	15.89	22.77
Total Current Assets	6,632	6,289	5,306	4,229	3,699	3,962
Property, Plant & Equipment	2,282	2,353	2,411	2,553	2,097	1,781
Long-Term Investments	16.21	16.44	16.78	16.98	17.73	18.35
Goodwill	-	-	-	-	-	214.84
Other Intangible Assets	372.51	286.89	316.8	331.14	278.21	294.16
Long-Term Deferred Tax Assets	175.88	259.46	358.08	486.31	545.66	430.01
Long-Term Deferred Charges	32.83	123.24	99.33	70.47	84.67	55.56
Other Long-Term Assets	21.21	14.48	22.01	33.93	233.89	245.29
Total Assets	9,533	9,342	8,530	7,721	6,956	7,001
Accounts Payable	265.26	297.16	344.03	409.54	343.13	288.87
Accrued Expenses	293.46	233.88	203.64	169.59	174.63	193.52
Current Portion of Leases	1.66	1.73	0.53	1.6	2.57	-
Current Income Taxes Payable	12.67	13.31	9.82	19.69	16.49	37.45
Current Unearned Revenue	17.19	8.92	5.1	9.14	8.39	11.84
Other Current Liabilities	56.18	99.98	91.31	84.1	122.16	448.02
Total Current Liabilities	646.42	654.99	654.43	693.66	667.37	979.7
Long-Term Leases	2.07	3.47	1.48	3.27	4.43	-
Long-Term Unearned Revenue	25.01	23.58	22.94	30.3	25.51	51.4
Long-Term Deferred Tax Liabilities	10.16	13.03	7.94	5.14	2.06	2.37
Other Long-Term Liabilities	-	-	30.96	81.48	151.71	211.88
Total Liabilities	683.67	695.07	717.76	813.85	851.08	1,245
Common Stock	921.3	919.78	919.46	919.46	919.46	919.46
Additional Paid-In Capital	2,028	1,997	1,990	1,994	1,986	1,981
Retained Earnings	5,915	5,738	4,896	3,989	3,185	2,856
Comprehensive Income & Other	-1.39	-1.33	-1.34	-1.05	-0.83	-0.4
Total Common Equity	8,863	8,653	7,804	6,902	6,090	5,756
Minority Interest	-13.9	-6.34	7.89	5.07	15.24	-
Shareholders' Equity	8,849	8,647	7,812	6,907	6,105	5,756
Total Liabilities & Equity	9,533	9,342	8,530	7,721	6,956	7,001
Total Debt	3.73	5.2	2.01	4.87	7	-
Net Cash (Debt)	5,995	5,684	4,700	3,681	3,132	3,328
Net Cash Growth	17.23%	20.94%	27.70%	17.52%	-5.88%	45.72%
Net Cash Per Share	6.54	6.20	5.13	4.02	3.42	3.82
Filing Date Shares Outstanding	921.3	919.78	919.46	919.46	919.46	919.46
Total Common Shares Outstanding	921.3	919.78	919.46	919.46	919.46	919.46
Working Capital	5,986	5,634	4,651	3,535	3,031	2,982
Book Value Per Share	9.62	9.41	8.49	7.51	6.62	6.26
Tangible Book Value	8,490	8,366	7,487	6,571	5,812	5,247
Tangible Book Value Per Share	9.22	9.10	8.14	7.15	6.32	5.71
Buildings	2,126	2,126	1,989	1,785	1,137	-
Machinery	1,285	1,271	1,236	1,088	830.91	-
Construction In Progress	126.26	112.35	166.54	475.88	808.69	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.